---
figid: PMC11989623__ijms-26-03438-g002
figtitle: Main mechanisms of resistance to ET and/or CDK4/6is in advanced ER+/HER2−
  breast cancer
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC11989623
filename: ijms-26-03438-g002.jpg
figlink: /pmc/articles/PMC11989623/figure/F2/
number: F2
caption: 'The main mechanisms of resistance to ET and/or CDK4/6is in advanced ER+/HER2−
  breast cancer. (a) These include ERBB2, FGFR1/2, EGFR, IGFR1, and NOTCH; (b) in
  Akt1, PI3KCA, PTEN, HRAS, KRAS, and NRAS; (c) ESR1 Y537S/Y537N mutations; RTK: receptor
  tyrosine kinase; PI3K: phosphoinositide 3 kinase; PTEN: phosphatase and tensin homolog;
  Akt: protein kinase B; mTOR: mammalian target of rapamycin; EGFR: epidermal growth
  factor receptor; ERBB2: receptor tyrosine-protein kinase erbB2; FGFR1/2: fibriblast
  growth factor receptor 1/2; IGFR1: insulin-like growth factor receptor 1; NOTCH:
  notch signaling pathway; MAPK: mitogen-activated protein kinase; Rb: retinoblastoma;
  RAS: rat sarcoma virus protein superfamily; NF1: neurofibromatosis type 1 gene;
  RAF: rapidly accelerated fibrosarcoma protein kinase; MEK: mitogen-activated protein
  kinase kinase; ERK: extracellular signal-regulated kinase; FAT1: protein encoded
  by FAT gene that takes part of the cadherin superfamily proteins; MST1/2: macrophage-stimulating
  protein 1/2; LATS1/2: large tumor suppressor kinase 1/2; YAP: yes-associated protein-1;
  TAZ: transcriptional adaptor putative zinc finger; TEAD: TEA domain family member;
  CDK: cyclin-dependent kinase; p: protein; SMAD4: smad family member 4; PMM2 m.r.;
  phosphomannomutase 2 metabolic reprogramming; APOBEC3 g.a.: apolipoprotein B mRNA-editing
  enzyme, catalytic subunit 3, genetic alteration; PKMYT: membrane-associated tyrosine
  and threonine specific cdc 2-inhibitory kinase; MYSM1: Myblike, SWIRM and MNP domain
  1; MNX1: motor neuron and pancreas homeobox 1; ACC1 m.r.: acetyl-CoA carboxylase
  1 metabolic reprogramming; CYP19A1: member of the cytochrome P450 superfamily; MLL3
  g.a.: myeloid lymphoid or mixed lineage leukemia protein 3 genetic alterations;
  COLL11A1: collagen, type XI, alpha 1; BCAR4: breast cancer anti-estrogen resistance
  protein 4; RFC3: replication factor C subunit 3; AEs: anti-estrogens; ERalpha: estrogen
  receptor alpha; ERE: estrogen receptor element; TATA: tiamine-adenine sequence;
  c-myc: family of genes overexpressed in various cancers and homologous with an avian
  virus; circHIAT1: circular RNA HIAT1; miR-19a-3p: microRNA 19a-3p; CADM2: cell adhesion
  molecule 2; NF-κB: nuclear factor kappa-light chain enhancer of activated B cells;
  AP-1: activating protein-1; E2F: transcription factor E2F; t.f.: franscription factor;
  HDAC: hystone deacetylase; LncRNA: long non-coding RNA; AURKA: aurora kinase A;
  CCNE1/2: genes encoding cyclin E1/E2 proteins; DNMT1: DNA methyltransferase 1; DDR:
  DNA damage repair; BRCA1/2: breast cancer type 1/2 genes; HRR: homologous recombination
  repair; HRD: homologous repair deficiency; TP53: tumor protein 53; DDCKPS: DNA damage
  checkpoints signaling; ATM: part of serine/threonine protein kinase ATM; ATR: ataxia-teleangectasia
  and RAD3 related; CHEK2: checkpoint kinase 2; PD-L1: programmed death ligand 1;
  TILs: tumor-infiltrating lymphocytes; IRPS: interferon-related palbociclib-resistance
  signature; IL: interleukin; P: phosphorylation. increase. Decrease. (Also see text)'
papertitle: Molecular Mechanisms and Therapeutic Strategies to Overcome Resistance
  to Endocrine Therapy and CDK4/6 Inhibitors in Advanced ER+/HER2− Breast Cancer
reftext: Paola Ferrari, et al. Int J Mol Sci. 2025 Apr;26(7).
year: '2025'
doi: 10.3390/ijms26073438
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: Multidisciplinary Digital Publishing Institute  (MDPI)
keywords: advanced ER+/HER2− breast cancer | endocrine therapy | CDK4/6 inhibitors
  | endocrine resistance
automl_pathway: 0.861502
figid_alias: PMC11989623__F2
figtype: Figure
redirect_from: /figures/PMC11989623__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11989623__ijms-26-03438-g002.html
  '@type': Dataset
  description: 'The main mechanisms of resistance to ET and/or CDK4/6is in advanced
    ER+/HER2− breast cancer. (a) These include ERBB2, FGFR1/2, EGFR, IGFR1, and NOTCH;
    (b) in Akt1, PI3KCA, PTEN, HRAS, KRAS, and NRAS; (c) ESR1 Y537S/Y537N mutations;
    RTK: receptor tyrosine kinase; PI3K: phosphoinositide 3 kinase; PTEN: phosphatase
    and tensin homolog; Akt: protein kinase B; mTOR: mammalian target of rapamycin;
    EGFR: epidermal growth factor receptor; ERBB2: receptor tyrosine-protein kinase
    erbB2; FGFR1/2: fibriblast growth factor receptor 1/2; IGFR1: insulin-like growth
    factor receptor 1; NOTCH: notch signaling pathway; MAPK: mitogen-activated protein
    kinase; Rb: retinoblastoma; RAS: rat sarcoma virus protein superfamily; NF1: neurofibromatosis
    type 1 gene; RAF: rapidly accelerated fibrosarcoma protein kinase; MEK: mitogen-activated
    protein kinase kinase; ERK: extracellular signal-regulated kinase; FAT1: protein
    encoded by FAT gene that takes part of the cadherin superfamily proteins; MST1/2:
    macrophage-stimulating protein 1/2; LATS1/2: large tumor suppressor kinase 1/2;
    YAP: yes-associated protein-1; TAZ: transcriptional adaptor putative zinc finger;
    TEAD: TEA domain family member; CDK: cyclin-dependent kinase; p: protein; SMAD4:
    smad family member 4; PMM2 m.r.; phosphomannomutase 2 metabolic reprogramming;
    APOBEC3 g.a.: apolipoprotein B mRNA-editing enzyme, catalytic subunit 3, genetic
    alteration; PKMYT: membrane-associated tyrosine and threonine specific cdc 2-inhibitory
    kinase; MYSM1: Myblike, SWIRM and MNP domain 1; MNX1: motor neuron and pancreas
    homeobox 1; ACC1 m.r.: acetyl-CoA carboxylase 1 metabolic reprogramming; CYP19A1:
    member of the cytochrome P450 superfamily; MLL3 g.a.: myeloid lymphoid or mixed
    lineage leukemia protein 3 genetic alterations; COLL11A1: collagen, type XI, alpha
    1; BCAR4: breast cancer anti-estrogen resistance protein 4; RFC3: replication
    factor C subunit 3; AEs: anti-estrogens; ERalpha: estrogen receptor alpha; ERE:
    estrogen receptor element; TATA: tiamine-adenine sequence; c-myc: family of genes
    overexpressed in various cancers and homologous with an avian virus; circHIAT1:
    circular RNA HIAT1; miR-19a-3p: microRNA 19a-3p; CADM2: cell adhesion molecule
    2; NF-κB: nuclear factor kappa-light chain enhancer of activated B cells; AP-1:
    activating protein-1; E2F: transcription factor E2F; t.f.: franscription factor;
    HDAC: hystone deacetylase; LncRNA: long non-coding RNA; AURKA: aurora kinase A;
    CCNE1/2: genes encoding cyclin E1/E2 proteins; DNMT1: DNA methyltransferase 1;
    DDR: DNA damage repair; BRCA1/2: breast cancer type 1/2 genes; HRR: homologous
    recombination repair; HRD: homologous repair deficiency; TP53: tumor protein 53;
    DDCKPS: DNA damage checkpoints signaling; ATM: part of serine/threonine protein
    kinase ATM; ATR: ataxia-teleangectasia and RAD3 related; CHEK2: checkpoint kinase
    2; PD-L1: programmed death ligand 1; TILs: tumor-infiltrating lymphocytes; IRPS:
    interferon-related palbociclib-resistance signature; IL: interleukin; P: phosphorylation.
    increase. Decrease. (Also see text)'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ESR1
  - ERAL1
  - MYC
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PTEN
  - NFIC
  - KRAS
  - HRAS
  - NRAS
  - EGFR
  - IFI27
  - PSMD9
  - ZNRD2
  - DCTN6
  - TMED7
  - H3P23
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - YAP1
  - TAFAZZIN
  - WWTR1
  - AKT1
  - AKT2
  - AKT3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - TEAD1
  - TEAD2
  - TEAD3
  - TEAD4
  - MTOR
  - RB1
  - RBM45
  - EPHB2
  - CDKN2A
  - H3P10
  - CDK4
  - CDK6
  - CCND1
  - CCND2
  - CCND3
  - E2F1
  - E2F2
  - E2F3
  - E2F4
  - E2F5
  - E2F6
  - E2F7
  - E2F8
  - AURKA
  - WARS1
  - LATS2
  - LATS1
  - SMAD4
  - PMM2
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - TF
  - HDAC4
  - TRA-TGC7-1
  - TIMM8A
  - MLRL
  - NF1
  - ACACA
  - BCL2A1
  - KMT2C
  - CYP19A1
  - BCAR4
  - COL11A1
  - CDK2
  - CCNE1
  - CCNE2
  - YBX1
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK5
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - DDR1
  - DDR2
  - TP53
  - BRCA2
  - BRCA1
  - CD274
  - TLR1
  - IL17A
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - ATM
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - CHEK2
  - RAS
  - MEK
---
